Intravitreal dexamethasone implants for diabetic macular edema

Area of Science:

• Ophthalmology
• Retinal Diseases
• Pharmacology

Background:

• Diabetic macular edema (DME) is a leading cause of vision loss in diabetic patients.
• Standard treatments for DME may not be effective for all patients.

Purpose of the Study:

• To assess the safety and efficacy of the dexamethasone (DEX) intravitreal implant in treating DME.
• To evaluate the implant's impact on visual acuity and macular thickness.

Main Methods:

• 113 eyes of 84 patients with DME received DEX intravitreal implants.
• Patients were categorized into naive, pseudophakic, and phakic subgroups.
• Best corrected visual acuity (BCVA), central macular thickness (CMT), and macular volume (MV) were measured over 12 months.

Main Results:

• Significant improvements in BCVA, CMT, and MV were observed at 1 and 3 months post-injection.
• Maximum efficacy was noted at 3 months, with progressive decline thereafter.
• Improvements remained statistically significant compared to baseline at 12 months; ocular complications were minimal.

Conclusions:

• The DEX intravitreal implant demonstrates significant efficacy in managing DME.
• Peak therapeutic effect occurs at 3 months, with sustained benefits over baseline at 12 months.
• The implant is a safe and effective option for DME patients refractory to standard treatments.